Related references
Note: Only part of the references are listed.In vivo and in vitro effects of a novel anti-Dkk1 neutralizing antibody in multiple myeloma
Samantha Pozzi et al.
BONE (2013)
Combination of bendamustine, lenalidomide, and dexamethasone (BLD) in patients with relapsed or refractory multiple myeloma is feasible and highly effective: results of phase 1/2 open-label, dose escalation study
Suzanne Lentzsch et al.
BLOOD (2012)
Bone Marrow Stromal Cells Create a Permissive Microenvironment for Myeloma Development: A New Stromal Role for Wnt Inhibitor Dkk1
Jessica A. Fowler et al.
CANCER RESEARCH (2012)
CD138-negative clonogenic cells are plasma cells but not B cells in some multiple myeloma patients
N. Hosen et al.
LEUKEMIA (2012)
Gfi1 expressed in bone marrow stromal cells is a novel osteoblast suppressor in patients with multiple myeloma bone disease
Sonia D'Souza et al.
BLOOD (2011)
A Gene Expression-Based Predictor for Myeloma Patients at High Risk of Developing Bone Disease on Bisphosphonate Treatment
Ping Wu et al.
CLINICAL CANCER RESEARCH (2011)
The serine/threonine kinase Pim-2 is a novel anti-apoptotic mediator in myeloma cells
J. Asano et al.
LEUKEMIA (2011)
MEDICAL PROGRESS Multiple Myeloma
Antonio Palumbo et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
DNAJB6 Induces Degradation of β-Catenin and Causes Partial Reversal of Mesenchymal Phenotype
Aparna Mitra et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2010)
Inhibiting Activin-A Signaling Stimulates Bone Formation and Prevents Cancer-Induced Bone Destruction In Vivo
Andrew D. Chantry et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2010)
First-line treatment with zoledronic acid as compared with clodronic acid in multiple myeloma (MRC Myeloma IX): a randomised controlled trial
Gareth J. Morgan et al.
LANCET (2010)
Of mice and men: divergent risks of teriparatide-induced osteosarcoma
V. Subbiah et al.
OSTEOPOROSIS INTERNATIONAL (2010)
TGF-β Inhibition Restores Terminal Osteoblast Differentiation to Suppress Myeloma Growth
Kyoko Takeuchi et al.
PLOS ONE (2010)
Activin A promotes multiple myeloma-induced osteolysis and is a promising target for myeloma bone disease
Sonia Vallet et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2010)
GM-CSF and IL-4 induce dendritic cell differentiation and disrupt osteoclastogenesis through M-CSF receptor shedding by up-regulation of TNF-α converting enzyme (TACE)
Masahiro Hiasa et al.
BLOOD (2009)
Anti-DKK1 mAb (BHQ880) as a potential therapeutic agent for multiple myeloma
Mariateresa Fulciniti et al.
BLOOD (2009)
A Novel Lung Metastasis Signature Links Wnt Signaling with Cancer Cell Self-Renewal and Epithelial-Mesenchymal Transition in Basal-like Breast Cancer
Theresa A. DiMeo et al.
CANCER RESEARCH (2009)
Bone marrow microenvironment and the identification of new targets for myeloma therapy
K. Podar et al.
LEUKEMIA (2009)
Inhibition of osteoblastic bone formation by nuclear factor-κB
Jia Chang et al.
NATURE MEDICINE (2009)
Giant osteoclasts after long-term bisphosphonate therapy: diagnostic challenges
Nidhi Jain et al.
NATURE REVIEWS RHEUMATOLOGY (2009)
Giant Osteoclast Formation and Long-Term Oral Bisphosphonate Therapy
Robert S. Weinstein et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Improved survival in multiple myeloma and the impact of novel therapies
Shaji K. Kumar et al.
BLOOD (2008)
Increasing Wnt signaling in the bone marrow microenvironment inhibits the development of myeloma bone disease and reduces tumor burden in bone in vivo
Claire M. Edwards et al.
BLOOD (2008)
Elevated tumor necrosis factor-α suppresses TAZ expression and impairs steogenic potential of Flk-1+ mesenchymal stem cells in patients with multiple myeloma
Bingzong Li et al.
STEM CELLS AND DEVELOPMENT (2007)
Therapy with bortezomib plus dexamethasone induces osteoblast activation in responsive patients with multiple myeloma
Shuji Ozaki et al.
INTERNATIONAL JOURNAL OF HEMATOLOGY (2007)
Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets
Teru Hideshima et al.
NATURE REVIEWS CANCER (2007)
c-Myc transforms human mammary epithelial cells through repression of the Wnt inhibitors DKK1 and SFRP1
Victoria H. Cowling et al.
MOLECULAR AND CELLULAR BIOLOGY (2007)
American Society of Clinical Oncology 2007 clinical practice guideline update on the role of bisphosphonates in multiple myeloma
Robert A. Kyle et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Antibody-based inhibition of DKK1 suppresses tumor-induced bone resorption and multiple myeloma growth in vivo
Shmuel Yaccoby et al.
BLOOD (2007)
Teriparatide [human PTH(1-34)]: 2.5 years of experience on the use and safety of the drug for the treatment of osteoporosis
AH Tashjian et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2006)
BMD and body composition in children and young patients affected by cystic fibrosis
ML Bianchi et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2006)
Tumor necrosis factor promotes Runx2 degradation through up-regulation of Smurf1 and Smurf2 in osteoblasts
H Kaneki et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2006)
Myeloma cells suppress bone formation by secreting a soluble Wnt inhibitor, sFRP-2
T Oshima et al.
BLOOD (2005)
Response to bortezomib is associated to osteoblastic activation in patients with multiple myeloma
M Zangari et al.
BRITISH JOURNAL OF HAEMATOLOGY (2005)
Myeloma cells block RUNX2/CBFA1 activity in human bone marrow osteoblast progenitors and inhibit osteoblast formation and differentiation
N Giuliani et al.
BLOOD (2005)
IL-3 is a potential inhibitor of osteoblast differentiation in multiple myeloma
LA Ehrlich et al.
BLOOD (2005)
The SCID-rab model:: a novel in vivo system for primary human myeloma demonstrating growth of CD138-expressing malignant cells
K Yata et al.
LEUKEMIA (2004)
Osteoclasts enhance myeloma cell growth and survival via cell-cell contact: a vicious cycle between bone destruction and myeloma expansion
M Abe et al.
BLOOD (2004)
The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma
E Tian et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis
DM Black et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
Selective inhibitors of the osteoblast proteasome stimulate bone formation in vivo and in vitro
IR Garrett et al.
JOURNAL OF CLINICAL INVESTIGATION (2003)
Molecular sequelae of proteasome inhibition in human multiple myeloma cells
N Mitsiades et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2002)
Cbfa1-independent decrease in osteoblast proliferation, osteopenia, and persistent embryonic eye vascularization in mice deficient in Lrp5, a Wnt coreceptor
M Kato et al.
JOURNAL OF CELL BIOLOGY (2002)
LDL receptor-related protein 5 (LRP5) affects bone accrual and eye development
YQ Gong et al.
CELL (2001)
Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis.
RM Neer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2001)
Share Paper
